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Focus Issue: Drug-Eluting
Stents and Thrombosis
No Late Risk for Stent Thrombosis Seen With DES STEMI
Some analyses have suggested that drug-eluting stents have higher rates of stentthrombosis when used for ST-segment elevation myocardial infarctions
(STEMIs). The STRATEGY trial randomized 175 patients with STEMI to either
tirofiban followed by sirolimus-eluting stent (SES) or abciximab plus bare-metal stent
(BMS). Over 2 years of follow-up, the incidence of death, MI, or target vessel
revascularization was lower in the SES compared with the BMS group (hazard ratio
0.56), mainly driven by the lower rate of target vessel revascularization (hazard ratio
0.34). Despite discontinuing thienopyridine use after an average of 6 months, there
were no differences in the rates of confirmed, probable, or possible stent thrombosis,
either early or late. An accompanying editorial reviews the evidence for the risk of stent
thrombosis with DES for STEMI and concludes that there is no increased risk seen in
randomized trials. See pages 138 and 146. See figure.
Coronary Artery Disease Risk
MPO Predictive of Future Cardiac Events in Healthy Individuals
Myeloperoxidase (MPO) exertsmany effects thatmay be proatherogenic, includ-ing oxidation of low-density lipoprotein, oxidativemodification of apolipopro-
tein A1, and reducing nitric oxide bioavailability. Meuwese and colleagues measured
MPO in baseline serum samples from a subgroup of the EPIC-Norfolk population
study. Cases were defined as apparently healthy men and women, who developed
coronary artery disease (CAD) during 8-years of follow-up. Controls werematched for
age, gender, and enrollment time and remained free of CAD. Myeloperoxidase levels
were significantly higher in cases than in controls. Risk of future CAD increased in
consecutive quartiles of MPO concentration, with an odds ratio (OR) of 1.49 in the
top versus bottom quartile and an OR of 1.82 for fatal CAD. This study further
validates the use of MPO to assess cardiac risk and extends its potential utility to
apparently healthy individuals. See page 159.
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Heart Rhythm Disorders
Predictive Value of Microvolt T-Wave Alternans in High-Risk Patients
Microvolt T-wave alternans (TWA) is an emerging technique to identify patientsat risk for sudden cardiac death. Cantillon and colleagues compared the ability
of TWA and traditional electrophysiologic testing (EPS) to predict arrhythmia-free
survival and totalmortality in patients with an ejection fraction35%and a history of
either nonsustained ventricular tachycardia and/or syncope. Arrhythmia-free survival
in TWA-negative patients was 81% versus 66% in subjects with non-negative TWA
study.The negative predictive value ofTWA for 2-yearmortalitywas 90%versus 83%
for EPS. An editorial by Klingenheben proposes that the predictive efficacy of the
TWA is largely dependent on the patient population studied and cautions that
recommendations regarding the clinical use of TWA need to be based on trials in
well-defined patient populations. See pages 166 and 174. See figure.
